Neurocrine director exercises 3,318 RSUs

NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin exercised restricted stock units into common shares.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at an exercise price of $0.00 per share. Following this compensation-related exercise, Sherwin directly holds 15,860 shares of Neurocrine common stock. The RSU award was granted on May 21, 2025 and is now fully vested, with no remaining units from this grant.

Insider Trade Summary

3,318 shares exercised/converted

Exercise 2 txns

Insider SHERWIN STEPHEN A

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	3,318	$0.00	$0.00
Exercise	Common Stock	3,318	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 15,860 shares (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
2. F2. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

Key Figures

RSUs exercised: 3,318 units Shares acquired: 3,318 shares Post-transaction holdings: 15,860 shares +2 more

5 metrics

RSUs exercised 3,318 units Restricted Stock Units converted to common stock on May 21, 2026

Shares acquired 3,318 shares Common stock received from RSU conversion at $0.00 per share

Post-transaction holdings 15,860 shares Total Neurocrine common stock directly held after RSU exercise

Exercise price $0.00 per share Conversion of RSUs into common stock

RSU grant date May 21, 2025 Original grant date of fully vested RSU award

Key Terms

Restricted Stock Unit, Common Stock, derivative security

3 terms

Restricted Stock Unit financial

"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Common Stock financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NBIX director Stephen A. Sherwin report?

Stephen A. Sherwin reported exercising 3,318 Restricted Stock Units into common stock. Each RSU converted into one Neurocrine Biosciences share, reflecting vesting of a prior equity grant. The transaction is compensation-related, not an open-market stock purchase or sale.

How many Neurocrine Biosciences (NBIX) shares does Stephen A. Sherwin now hold?

After the RSU conversion, Stephen A. Sherwin directly holds 15,860 shares of Neurocrine Biosciences common stock. This total reflects the addition of 3,318 newly issued shares from vested Restricted Stock Units reported in the Form 4 insider filing.

What was the size and nature of the NBIX RSU transaction on May 21, 2026?

On May 21, 2026, 3,318 Restricted Stock Units were exercised into 3,318 Neurocrine Biosciences common shares. The transaction used code “M,” indicating an exercise or conversion of a derivative security, rather than an open-market stock trade by the director.

Were Neurocrine Biosciences (NBIX) shares bought or sold on the market in this Form 4?

No market purchases or sales occurred in this Form 4. The filing shows an exercise of 3,318 Restricted Stock Units into common stock at $0.00 per share, a vesting-related conversion, with no reported open-market buy or sell transactions.

When was the RSU award to NBIX director Stephen A. Sherwin originally granted and what is its status?

The Restricted Stock Unit award was granted on May 21, 2025 and is now fully vested. All 3,318 RSUs have been converted into Neurocrine Biosciences common stock, leaving no remaining units from this specific equity grant outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 07:24 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHERWIN STEPHEN A

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		M		3,318	A	$0	15,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0(1)	05/21/2026		M			3,318	(2)	(2)	Common Stock	3,318	$0	0	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)